Abstract:Purpose: This study evaluated the clinical outcomes of patients with hepatocellular carcinoma (HCC) with hepatic vein tumor thrombus (HVTT) and/or inferior vena cava tumor thrombus (IVCTT) receiving radiotherapy (RT) combined with systemic therapies. Patients and methods: Patients with HCC with HVTT and/or IVCTT who received RT were identified at our institution. The prescription doses were 30-65 Gy for planning target volume and 40-65 Gy for the gross tumor volume. Targeted therapy and immune checkpoint inhibitors were used concurrently if patients were at a high risk of or already had distant metastasis. After RT completion, follow-up was performed at 1, 3, 6, and 12 months, and 3 to 6 months thereafter. The objective response rate (ORR), overall survival (OS), progression-free survival (PFS) and toxicity were recorded. Results: Thirty-four patients were retrospectively enrolled between January 2016 and September 2021. Most patients received concurrent targeted therapy (70.6%) and/or post-RT (79.4%). The in-field ORR and disease control rates were 79.4% and 97.1%, respectively. The OS rates were 77.6% at 1 year and 36.3% at 2 years (median OS, 15.8 months). The median PFS and median in-field PFS were 4.2 months and not reached, respectively. The PFS and in-field PFS rates were 24.6% and 79.2% at 1 year, 19.7% and 72.0% at 2 years, respectively. An alpha-fetoprotein level >1000 ng/mL was a significant prognostic factor for worse OS (HR, 5.674; 95% CI, 1.588-20.276; p=0.008); in-field complete/partial response was a significant prognostic factor for better OS (HR, 0.116; 95% CI, 0.027-0.499; p=0.004). The most common site of first failure was the lungs (13/34 patients, 38.2%), followed by the liver (7/34 patients, 20.6%). No patients developed radiation-induced liver disease or pulmonary embolism during follow-up. Conclusion: Combining RT and systemic therapy was safe and effective in treating patients with HCC with HVTT and IVCTT.

Advances in gross tumor target volume determination in radiotherapy for patients with hepatocellular carcinoma

Postoperative Radiotherapy For Glioma: Improved Delineation Of The Clinical Target Volume Using The Geodesic Distance Calculation

Advances in determining the gross tumor target volume for radiotherapy of brain metastases

Automated Clinical Target Volume Delineation Using Deep 3D Neural Networks in Radiation Therapy of Non-small Cell Lung Cancer

Ultrasonography of Hepatocellular Carcinoma: From Diagnosis to Prognosis

Image-guided locoregional non-intravascular interventional treatments for hepatocellular carcinoma: Current status

To Study the Feasibility of Defining the Internal Gross Tumor Volume for Hepatocellular Carcinoma Applying the Enhanced 4DCT Images Obtained by Deformable Registration Technology

Recent Advances in Hepatocellular Carcinoma Therapeutic Strategies and Imaging-Guided Treatment

A Recent Advance in Image-Guided Locoregional Therapy for Hepatocellular Carcinoma

Advances in radiotherapy and immunity in hepatocellular carcinoma

Advanced Imaging Techniques in the Therapeutic Response of Transarterial Chemoembolization for Hepatocellular Carcinoma

Proton Beam Therapy and Photon-Based Magnetic Resonance Image-Guided Radiation Therapy: The Next Frontiers of Radiation Therapy for Hepatocellular Carcinoma

Radiotherapy with Targeted Therapy or Immune Checkpoint Inhibitors for Hepatocellular Carcinoma with Hepatic Vein and/or Inferior Vena Cava Tumor Thrombi

New advances in the treatment of intermediate and advanced hepatocellular carcinoma

P29.05 Gross Tumor Volume Contouring Variations in Radiation Therapy of Non-Small Cell Lung Cancer

Exploiting targeted nanomedicine for surveillance, diagnosis, and treatment of hepatocellular carcinoma

Advances of Targeted Therapy for Hepatocellular Carcinoma

Recent Advances in the Studies of Hepatocellular Carcinoma

Challenges in the target volume definition of lung cancer radiotherapy

Recent Advances in Tumor Ablation for Hepatocellular Carcinoma

Prospective Evaluation of Microscopic Extension Using Whole-mount Preparation in Patients with Hepatocellular Carcinoma: Definition of Clinical Target Volume for Radiotherapy